secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001762303-25-000012
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q2 revenue $18.4M (+21% YoY); slashes FY2025 revenue guidance to $76M-$81M, delays profitability to 2026
--------------------------------------------------------------------------------

- Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.
- FY2025 revenue guidance reduced to $76M-$81M (prior $100M-$106M) due to MAC payment backlog affecting RECELL demand.
- Fifth amendment to OrbiMed credit agreement: TTM revenue covenants lowered through Q2 2026; 400,000 common shares issued in lieu of cash fee.
- Michael Tarnoff appointed to Board of Directors; adds healthcare leadership experience.
- Clinical highlight: RECELL reduces hospital stays 36%; CMS NTAP approved for inpatient trauma wounds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000176230325000012/0001762303-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000176230325000012/rcel-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001762303-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer